Bringing primary cells to mainstream drug development and drug testing

Area of Science:

• Drug discovery and development
• Cell biology
• Pharmacology

Background:

• Current cell-based screening models in drug discovery are increasingly inadequate.
• Transformed cell models are widely used but lack disease relevance.
• Patient-derived primary cells represent a more accurate and disease-oriented alternative.

Purpose of the Study:

• To review enabling technologies for using patient-derived primary cells in drug discovery.
• To explore critical applications of primary cells in drug discovery and testing.
• To highlight the potential of primary cells to transform drug development.

Main Methods:

• Review of recent technological advancements in cell isolation and culture.
• Analysis of improvements in assay miniaturization, transfection efficiency, and sensitivity.
• Examination of case studies and applications of primary cells in screening.

Main Results:

• Technological progress has overcome previous limitations of primary cell scarcity and handling.
• Primary cells are now feasible for mainstream drug discovery pipelines.
• These advancements enable more relevant and predictive drug screening.

Conclusions:

• Patient-derived primary cells are poised to become the next standard in drug discovery.
• Enabling technologies are crucial for realizing the full potential of primary cells.
• The shift to primary cells promises more effective drug testing and development.